dr. patel on differences between btk inhibitors in mcl
Published 5 years ago • 54 plays • Length 1:16Download video MP4
Download video MP3
Similar videos
-
1:26
dr. patel discusses zanubrutinib in mcl
-
1:45
dr. patel discusses promise of acalabrutinib in mcl
-
5:59
differentiating btk inhibitor mechanisms of action in mcl
-
1:56
dr. rule on the role of btk inhibitors in mcl
-
1:57
dr. patel on ibrutinib in real-world setting versus clinical trials
-
1:29
dr. wang on the benefit of btk inhibitors in mcl
-
1:05
dr. furman on differences between btk inhibitors in b-cell malignancies
-
0:55
dr. smith on safety profiles of btk inhibitors in mcl
-
5:07
btk inhibitors in mcl: aes, specificity, and interactions
-
1:13
dr. goy on research efforts with btk inhibitors in mcl
-
1:00
identifying differences between btk inhibitors for b-cell malignancies
-
1:47
dr. leslie on the role of btk inhibitors in relapsed/refractory mcl
-
4:13
mcl: novel btk inhibitor combination strategies
-
1:10
dr. wang on the toxicity of ibrutinib, acalabrutinib, and zanubrutinib in mcl
-
1:05
dr. fenske on the utility of next-generation btk inhibitors in mcl
-
4:03
mcl: fda approval of a second-generation btk inhibitor
-
5:40
first-generation btk inhibition in mantle cell lymphoma
-
1:27
dr. patel on induction in patients with mantle cell lymphoma
-
5:11
safety and efficacy of btk inhibitors in r/r mcl